InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,889.20
(
0.49%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.42
(
-0.21%
)
Bitcoin
62,456.93
(
2.74%
)
Post# of 252595
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120032
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 220122

Friday, 08/10/2018 6:44:10 PM

Friday, August 10, 2018 6:44:10 PM

Post# of 252595
Mavyret’s US new-patient share=51.5%—the highest-ever weekly figure—in the week ending 8/3/18, as reported by IMS. GILD’s US new-patient share was 47.4%, and MRK’s was 1.1%.

Mavyret’s US total-script share reached 45.6% in the week ending 8/3/18, also the highest-ever weekly figure, as reported by IMS. GILD’s US total-script share was 52.8%, and MRK’s was 1.6%.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up